Raltegravir-Based Third-Line ART in Children and Adolescents
October 1, 2016
Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.
The number of HIV-positive children and adolescents failing second-line ART is increasing, leading to resistance to protease inhibitors. There are limited data describing response to raltegravir (RAL)-based third-line ART among children in low- and middle-income settings.
Victor Musiime described outcomes of five children and adolescents receiving RAL-based ART at Joint Clinical Research Centre (JCRC), Kampala, Uganda. These case studies were presented at the Global HIV Clinical Forum: Integrase Inhibitors meeting before IAS2016.
The investigators performed a chart and database review of children and adolescents less than 18 years of age attending JCRC with second-line failure; triple class antiretroviral drug resistance (NRTI, NNRTI and PI); and on RAL-based third-line ART.
Those that fulfilled the selection criteria underwent an assessment of: weight, CD4 count, viral load and World Health Organization (WHO) clinical stage at baseline and after switching to RAL-based ART. The investigators also reviewed the case histories and genotypic resistance test results before switching. Follow up was for a minimum of six and maximum of 54 months.
Of five cases evaluated, four were male and one was female. They switched to RAL at 9-15 years of age. Their third-line regimens were: darunavir/ritonavir (DRV/r) + RAL, n=3; etravirine (ETR) + DRV/r+ RAL, n=1; tenofovir DF (TDF) + lamivudine (3TC) + DRV/r + RAL (n=1).
All had received 2 NRTIs + 1 NNRTI first-line, and lopinavir/ritonavir (LPV/r)- based second-line ART. Each case had developed: 5 or more NRTI resistance associated mutations (RAMs); 2 or 3 NNRTI RAMs (n=4) and 1 NNRTI RAM (n=1); and 3 or 4 PI RAMs.
The investigators reported that all of the five children and adolescents evaluated achieved viral suppression, as well as increased weights and CD4 counts; none developed new WHO stage III/IV events after switching to RAL-based third-line ART.
Musiime V et al. Response to raltegravir based third-line antiretroviral therapy among Ugandan children: A case series from an urban HIV clinic. Global HIV Clinical Forum: Integrase Inhibitors. 16 July 2016, Durban, South Africa. Oral abstract O_04.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.